| Name | Title | Contact Details |
|---|
Display It is a Cave Creek, AZ-based company in the Business Services sector.
PUSEN is on a mission to tackle healthcares biggest challenges. We collaborate with healthcare professionals globally to develop innovative solutions for debilitating and life-threatening conditions. Our goal? Enhance patient lives and medical professionals. Across 100+ countries, we make a difference by: Empowering providers: We support healthcare professionals by delivering solutions that reduce costs, boost efficiency, and expand access to care. This allows them to help more people, in more places, live longer and healthier lives. Improving patient outcomes: Our solutions address critical medical needs, offering hope and improved quality of life to patients facing difficult diagnoses. Want to learn more? Visit our North American website, PUSEN USA, at www.pusenusa.com
RFI Corp is a Bay Shore, NY-based company in the Business Services sector.
ADP Automotive Warehouse Inc is a Saddle Brook, NJ-based company in the Business Services sector.
TIXiMED, Inc. is focused on developing and commercializing TXNIP inhibiting medication as a first-of-its-kind oral therapeutic for Type 1 and Type 2 diabetes. TIXiMED is the exclusive license holder for the patent (composition of matter and method of use) surrounding TIX100, a novel small molecule that normalizes pancreatic beta cell TXNIP, a detrimental protein elevated in Type 1 and Type 2 diabetes. Increased TXNIP causes pancreatic islet dysfunction and death of insulin-producing beta cells and thereby contributes to the development and progression of diabetes. Diabetes affects more than half a billion people worldwide. Those affected by Type 1 diabetes are dependent on multiple daily insulin injections or continuous insulin infusions to stay alive and manage their blood sugar. Oral anti-diabetic drugs are only approved for Type 2 diabetes, but can be associated with multiple side effects, underlining the need for novel and better oral diabetes medications for Type 1 and Type 2 diabetes. TXNIP inhibition has recently been demonstrated to be an effective and safe therapeutic approach in adults and children with recent onset Type 1 diabetes and TIX100 shows beneficial, anti-diabetic effects in 4 different mouse models. Advantages of TIX100 include oral availability, no associated hypoglycemia or weight gain, potent inhibition of detrimental TXNIP in human islets, and a favorable pharmacokinetic and safety profile. In addition, TIX100 inhibits excessive glucagon secretion and hepatic glucose production and protects against fatty liver. Thus, TIX100 holds promise for durable, weight-neutral improvement in glycemic control in Type 1 and Type 2 diabetes by targeting common underlying pathology and promoting patients own islet cell health.